Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
Clinical Outcomes and Surgical Procedures for Patients With Osteosarcoma and Metachronous Lung Metastasis: A Chronological Analysis.
PMID 41447363 Published: 2025-12-25 Ingested: 2026-08-02 12:05 AM Journal of surgical oncology
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 54.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
The development of CAR T cells for patients with CNS malignancies.
PMID 41326789 Published: 2025-12-01 Ingested: 2026-08-02 12:05 AM Nature reviews. Clinical oncology
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Dordaviprone.
PMID 41239907 Published: 2025-11-15 Ingested: 2026-08-02 12:05 AM Journal of clinical pharmacology
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.
PMID 41218854 Published: 2025-11-11 Ingested: 2026-08-02 12:05 AM Journal for immunotherapy of cancer
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 79.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma.
PMID 41007693 Published: 2025-08-31 Ingested: 2026-08-02 12:05 AM Biomedicines
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 34.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
Ultrasonography Combined With Sonoelastography Strain Ratio for the Differentiation of Parotid Masses.
PMID 40785587 Published: 2025-08-11 Ingested: 2026-08-02 12:04 AM Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
Catatonia: American Psychiatric Association Resource Document.
PMID 40368005 Published: 2025-05-12 Ingested: 2026-08-02 12:04 AM Journal of the Academy of Consultation-Liaison Psychiatry
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 75.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 24.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART.
PMID 39018630 Published: 2024-07-14 Ingested: 2026-08-02 12:02 AM European journal of cancer (Oxford, England : 1990)
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

B
Features Associated With High Risk of Recurrence in Saccular Laryngeal Cysts: A Systematic Review and Qualitative Synthesis.
PMID 37903687 Published: 2023-10-29 Ingested: 2026-08-02 12:06 AM Journal of voice : official journal of the Voice Foundation
AI -
Standard 74.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.3/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 34.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

Previous
Page 423 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic